Development of Artificial Cell Can Cause Organ-Specific Accumulation and Lesion Healing

Request Number REQ7368605
Due Date March 27, 2018
Request for Proposal Details
RFP Title
Development of Artificial Cell Can Cause Organ-Specific Accumulation and Lesion Healing
RFP Description

NineSigma, representing a Japanese pharmaceutical company, seeks a joint development partner to develop cellular medicine that can be accumulated in a specific organ or legion area autonomously and cure disease (multifunctional artificial organ precursor cells).


Currently, the client anticipates development of multifunctional artificial organ precursor cells by combining all of the following 4 technologies; however, at this point, organizations conducting R&D of either one of these technologies will be welcome as potential joint development partners.


  1. Technology that enables cells administered to the patient systemically to be accumulated in a specific lesion or organ autonomously
  • Technology to improve the disease organ -specific recruitment and accumulation of cells by analyzing and applying the damaged site-specific migration potency possessed by bone marrow stem cells, etc.


  1. Technology that can detect and evaluate the severity and condition of organ impairment like a molecular sensor
  • Should be able to sense secretions and changes in a legion microenvironment


  1. Technology that can control the expression of genetic tools embedded in cells at an optimal timing and intensity, depending on a signal transmitted from a molecular sensor
  • Should be able to induce the expression of multiple genetic tools required for damage repair and tissue regeneration in optimal combination, based on information detected by a molecular sensor


  1. Technology that can control autonomous proliferation and differentiation activity of administrated cells, depending on a stimulation transmitted from a molecular sensor
  • Should induce proliferation and differentiation to the variety of organ cells, which are required for damage repair and tissue regeneration, based on information detected by a molecular sensor



Key Success Criteria

Requirements to be fulfilled in collaboration with potential partners

The client aims at commercialization of artificial cells for organ treatment, controlled by Chimeric Artificial Receptor (CAR) that fulfills the following requirements, in collaboration with potential partners:

  • CAR that can impart target organ directivity
    • More than 50% of systemically administered cells to be accumulated in the target organ or lesion area selectively
  • CAR enables embedded therapeutic genes to be expressed responding to the condition of surrounding environment
    • Recognize the initial disease environment, produce multiple factors required for treatment in optimal combination and amount, and then stop production of the factors by detecting the recovered environment
  • CAR that can induce proliferation and  differentiation of administrated cells toward organ-specific cells
    • At a necessary timing, cause proliferation of the cells in an appropriate amount, their differentiation to target cells and development of resultant organ functions under the control of environment recognition molecular sensor.
  • Artificial cell that can execute the above 3 CAR functions in single cell, sequentially in this order



Preferred Collaboration types
  • Joint Development
  • Technology Licensing
Items to be submitted

Responses will use the Proposal Template which is linked to the “attachments” shown at the bottom of this page and include the following items:


  • Overview of the technology (background of development, anticipated applications at the time of development, uniqueness, etc.)
  • Current performance
    • Type of technology
    • Mechanism of the functional expression
    • Actual data obtained using the proposed technology
  • Current R&D stage
  • R&D plan
  • Request regarding the condition of collaboration
  • Current status of intellectual property related to the proposed technology
  • Research achievements


Anticipated Project Phases or Project Plan

Respondents should submit proposals using the attached Response Template.


The client will review submitted proposals and possibly ask clarifying questions before selecting the most suitable candidates for collaboration. The client will select the best candidate(s) through evaluations. During the selection process, the client may execute non-disclosure agreements (NDA) with selected respondent(s), seek further information disclosure, and discuss specific development targets or potential opportunities.

The client will execute necessary agreement(s) with the selected respondent(s) and move to the advanced development phase. Specifics of any collaboration will be determined through consultation with the concerned parties.



Area of Interest
Request Priority